Colorectal Cancer

Colorectal Cancer – Medical Student Study Guide

Definition

Colorectal cancer (CRC) is a malignant epithelial tumor arising from the mucosal lining of the colon or rectum, most commonly adenocarcinoma. It typically develops from precursor lesions such as adenomatous polyps or serrated polyps through a stepwise accumulation of genetic and epigenetic alterations (adenoma–carcinoma sequence).

Epidemiology

Colorectal cancer is among the most common cancers worldwide and a leading cause of cancer-related mortality. Incidence increases markedly after age 50, although early-onset CRC (<50 years) is rising. Most cases are sporadic, but a significant minority are associated with hereditary syndromes or strong family history. Environmental and lifestyle factors (diet, obesity, physical inactivity, smoking, alcohol) contribute substantially to risk. Use of statins has been investigated for potential prognostic and survival benefits in CRC, although evidence remains mixed and heterogeneous across studies.[8](https://europepmc.org/article/MED/41663946)

Pathophysiology

CRC develops through several well-described molecular pathways that drive transformation of normal epithelium to invasive carcinoma:

• Chromosomal instability (CIN) / adenoma–carcinoma sequence: The classic pathway involves APC tumor suppressor gene inactivation followed by KRAS activation and TP53 loss, leading to progressive dysplasia and eventual invasive carcinoma.
• Microsatellite instability (MSI) pathway: Caused by defects in DNA mismatch repair (MMR) genes (e.g., MLH1, MSH2, MSH6, PMS2), either germline (Lynch syndrome) or somatic promoter hypermethylation. MSI-high tumors often arise in the proximal colon, exhibit lymphocytic infiltration, and have a distinct response profile to immunotherapy.
• Serrated pathway: Characterized by BRAF mutations and CpG island methylator phenotype (CIMP), often arising from sessile serrated lesions, particularly in the right colon.
• Tumor microenvironment and immune regulation: Metabolic reprogramming and immune evasion are key features. For example, overexpression of arginase 2 (ARG2) in CRC has been shown to activate the PI3K/AKT pathway, promoting invasion and metastasis, while also modulating immune cell infiltration, supporting tumor progression.[5](https://pubmed.ncbi.nlm.nih.gov/41635003/)
• RNA modification and post-transcriptional regulation: m⁶A-dependent stabilization of oncogenic transcripts contributes to CRC progression. SERPINA4 has been identified as an m⁶A-regulated factor that enhances CRC cell growth and invasion by stabilizing pro-tumorigenic mRNAs, underscoring the importance of epitranscriptomic regulation in colorectal tumor biology.[7](https://europepmc.org/article/MED/41764519)
• Cell death and autophagy pathways: Regulators of mitophagy and apoptosis such as NIX/BNIP3L have dual roles in tumor biology, either restraining tumorigenesis via promotion of cell death or facilitating tumor survival and adaptation under stress, depending on context and tumor stage.[3](https://pubmed.ncbi.nlm.nih.gov/41744611/)

Hereditary forms involve germline mutations (e.g., APC in familial adenomatous polyposis, MMR genes in Lynch syndrome) with early and accelerated polyp–carcinoma progression.

Clinical Presentation

Symptoms often depend on tumor location (right vs left colon vs rectum) and disease stage. Early disease is frequently asymptomatic and detected via screening.

• Right-sided (proximal) colon cancers:
  • Occult gastrointestinal bleeding leading to iron-deficiency anemia (fatigue, pallor, exertional dyspnea).
  • Vague abdominal pain or discomfort.
  • Weight loss, anorexia.
  • Often present later due to wider lumen and liquid stool.
• Left-sided (distal) colon cancers:
  • Change in bowel habits (new-onset constipation, narrow caliber stool, alternating diarrhea and constipation).
  • Visible rectal bleeding or hematochezia mixed with stool.
  • Colicky abdominal pain, signs of partial obstruction.
• Rectal cancers:
  • Hematochezia or mucus per rectum.
  • Tenesmus, sensation of incomplete evacuation.
  • Pelvic or rectal pain in advanced disease.
• Systemic and advanced disease features:
  • Unintentional weight loss, anorexia, fatigue.
  • Hepatomegaly or liver dysfunction (liver metastases).
  • Dyspnea, cough (lung metastases), bone pain (bone metastases).
  • Peritonitis or acute obstruction in emergencies (perforation, complete obstruction).

Diagnosis

Initial Evaluation

Diagnosis begins with a detailed history (including red-flag symptoms, family history, and risk factors) and physical examination, including digital rectal exam (DRE) and assessment for anemia or weight loss. Laboratory tests often include complete blood count (to detect iron-deficiency anemia), liver function tests, and baseline renal function.

Definitive Diagnosis

• Colonoscopy with biopsy (gold standard):
  • Allows direct visualization of the entire colon and rectum.
  • Permits biopsy of suspicious lesions and polypectomy of precancerous polyps.
  • Histology typically shows adenocarcinoma with varying differentiation.
• Flexible sigmoidoscopy: Useful when full colonoscopy is not immediately feasible, particularly in distal disease, but must usually be followed by full colonoscopy for complete evaluation.
• Non-invasive screening tests: Fecal immunochemical test (FIT), guaiac-based fecal occult blood test (gFOBT), and stool DNA tests are used primarily for screening rather than definitive diagnosis. Positive results mandate diagnostic colonoscopy.

Staging and Imaging

Once CRC is confirmed histologically, staging is performed using the TNM system (Tumor, Node, Metastasis) to guide therapy and prognosis.

• CT scan (chest, abdomen, pelvis): Assesses local extension, nodal involvement, and distant metastases (commonly liver and lungs).
• MRI pelvis: Standard for local staging of rectal cancers (depth of invasion, circumferential resection margin, mesorectal fascia involvement).
• Endorectal ultrasound: Alternative for early rectal tumor staging (T and N stage) when MRI is unavailable.
• Tumor markers: Carcinoembryonic antigen (CEA) is used for baseline and follow-up, although it is not diagnostic and can be normal in early disease.
• Molecular profiling: Testing for RAS (KRAS/NRAS), BRAF, MMR/MSI status, and sometimes HER2 is now standard for advanced disease to guide targeted and immunotherapy selection.

Management

Management of CRC is stage-dependent and multidisciplinary, combining surgery, systemic therapy, and radiation (especially for rectal tumors).

Surgical Management

• Localized colon cancer (stages I–III):
  • Standard treatment: Oncologic resection with lymphadenectomy (segmental colectomy with high ligation of feeding vessels and removal of ≥12 lymph nodes when possible).
  • Surgical approach may be open, laparoscopic, or robotic depending on expertise and patient factors.
• Rectal cancer:
  • Principle: Total mesorectal excision (TME) to remove the rectum and surrounding mesorectal envelope.
  • Procedures include low anterior resection (LAR) with colorectal or coloanal anastomosis, or abdominoperineal resection (APR) with permanent colostomy when sphincter preservation is not feasible.
• Metastatic disease:
  • Resection of isolated liver or lung metastases can be considered in selected patients and may be potentially curative.
  • Palliative surgeries are used for obstruction, perforation, or bleeding when systemic therapy alone is insufficient.

Systemic Therapy

• Adjuvant chemotherapy:
  • Indicated in most stage III colon cancers and selected high-risk stage II (e.g., T4, poor differentiation, lymphovascular invasion, <12 nodes examined).
  • Common regimens include FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) or CAPOX (capecitabine, oxaliplatin).
  • In rectal cancer, adjuvant therapy is individualized based on response to neoadjuvant chemoradiation and surgical pathology.
• Neoadjuvant therapy in rectal cancer:
  • Chemoradiation (e.g., 5-FU–based or capecitabine with pelvic radiation) is standard for locally advanced rectal cancer (T3/T4 or N+), reducing local recurrence and often downstaging tumors.
  • “Total neoadjuvant therapy” (TNT) protocols deliver systemic chemotherapy and chemoradiation preoperatively.
• First-line therapy in metastatic CRC:
  • Backbone regimens: FOLFOX, FOLFIRI (5-FU, leucovorin, irinotecan), or FOLFOXIRI, often combined with targeted agents depending on molecular profile.
  • Biologic agents include bevacizumab (anti-VEGF), and EGFR inhibitors (cetuximab, panitumumab) for RAS wild-type left-sided tumors.
  • Novel multimechanistic conjugates that combine cytotoxic backbones (e.g., 10-hydroxycamptothecin derivatives) with additional anticancer moieties are under investigation to enhance efficacy and reduce toxicity in CRC therapy.[9](https://europepmc.org/article/MED/41725280)
• Immunotherapy:
  • Immune checkpoint inhibitors (e.g., PD-1 inhibitors) are effective in MSI-high/dMMR metastatic CRC and are increasingly used in this molecular subset.
  • Microsatellite-stable (MSS) tumors generally have limited response to single-agent immunotherapy, though combination strategies are being studied.

Radiation Therapy

• Rectal cancer: Radiation is a cornerstone for locally advanced rectal cancer, used as long-course chemoradiation or short-course radiotherapy, to reduce local recurrence and improve resectability.
• Colon cancer: Radiation has a limited role, mainly in palliative settings for unresectable local recurrences or symptom control (e.g., bone metastases).

Prognostic and Emerging Factors

Prognosis is primarily determined by stage at diagnosis (depth of invasion, nodal involvement, metastases), but molecular and metabolic factors are increasingly recognized:

• Metabolic enzymes: ARG2-driven activation of PI3K/AKT and its association with altered immune infiltration highlight the prognostic significance of metabolic reprogramming in CRC.[5](https://pubmed.ncbi.nlm.nih.gov/41635003/)
• Epigenetic and epitranscriptomic markers: m⁶A-regulated genes such as SERPINA4 are associated with aggressive tumor behavior and may represent therapeutic targets and prognostic biomarkers.[7](https://europepmc.org/article/MED/41764519)
• Host and prior therapy factors: Observational data suggest that statin use may be associated with improved CRC-specific and overall survival in some cohorts, potentially via effects on tumor cell proliferation and the tumor microenvironment, though findings remain inconsistent and not yet practice-changing.[8](https://europepmc.org/article/MED/41663946)

Key Clinical Pearls

• Screening saves lives: CRC often progresses through a prolonged adenoma–carcinoma sequence, making it highly amenable to prevention and early detection via colonoscopy and other screening modalities. Trial data and public communication (e.g., NordICC trial) have shaped perceptions about colonoscopy effectiveness, emphasizing that screening reduces CRC incidence and mortality even though absolute risk reductions can appear modest in population-level presentations.[10](https://europepmc.org/article/MED/39907707)
• Always consider CRC in iron-deficiency anemia: Occult GI blood loss from right-sided CRC is a classic cause of unexplained iron-deficiency anemia in adults, particularly in older patients.
• Location matters: Right-sided, left-sided, and rectal tumors differ in symptoms, molecular profile, and therapeutic response (e.g., anti-EGFR benefit largely in left-sided RAS wild-type tumors).
• Family history and hereditary syndromes: A strong family history or early-onset CRC should prompt evaluation for hereditary syndromes and tailored surveillance of relatives.
• Molecular testing is standard in advanced disease: RAS/BRAF status, MSI/MMR, and sometimes HER2 must be known to select appropriate targeted therapies and immunotherapy.
• Multidisciplinary care is crucial: Optimal management requires coordination between gastroenterology, surgery, medical oncology, radiation oncology, radiology, and pathology, particularly for rectal and metastatic disease.

Summary

Colorectal cancer is a common and potentially preventable malignancy with well-defined molecular pathways and effective screening strategies. Understanding its pathophysiology, clinical presentation, diagnostic work-up, and stage-based management is essential for medical students. Emerging data on metabolic, epigenetic, and microenvironmental drivers of CRC are expanding therapeutic options and refining prognostication, reinforcing the importance of integrating molecular insights into clinical practice.[3](https://pubmed.ncbi.nlm.nih.gov/41744611/) [5](https://pubmed.ncbi.nlm.nih.gov/41635003/) [7](https://europepmc.org/article/MED/41764519/)